{
    "clinical_study": {
        "@rank": "25010", 
        "acronym": "SYMPHONYext", 
        "arm_group": {
            "arm_group_label": "Macitentan", 
            "arm_group_type": "Experimental", 
            "description": "Macitentan tablet, dose of 10 mg, once daily."
        }, 
        "brief_summary": {
            "textblock": "SYMPHONY Extension is an extension of AC-055-401, a multi-center, open-label, single-arm,\n      Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to\n      psychometrically validate the PAH-SYMPACT instrument. The objective is to assess the\n      long-term safety of macitentan in subjects with PAH beyond the treatment in the AC-055-401\n      study."
        }, 
        "brief_title": "AC-055-402: An Extension of AC-055-401, Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Pulmonary Arterial Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent prior to any study-mandated procedure.\n\n          -  Patients with PAH who completed study AC-055-401\n\n          -  Women of childbearing potential must:\n\n          -  Have a negative urine pregnancy test at Visit 1 and agree to perform monthly serum\n             pregnancy tests.\n\n          -  Agree to use two methods of contraception from Visit 1 until 1 month after study drug\n             discontinuation.\n\n        Exclusion Criteria:\n\n          -  Patients who prematurely discontinued study drug in study AC-055-401\n\n          -  Females who are lactating or pregnant (positive Visit 1 pregnancy test) or plan to\n             become pregnant during the study\n\n          -  Known hypersensitivity to macitentan or its excipients or drugs of the same class"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847014", 
            "org_study_id": "AC-055-402"
        }, 
        "intervention": {
            "arm_group_label": "Macitentan", 
            "description": "Macitentan tablet, dose of 10 mg, once daily.", 
            "intervention_name": "Macitentan", 
            "intervention_type": "Drug", 
            "other_name": "ACT-064992"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Pulmonary Arterial Hypertension (PAH)", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }, 
                    "name": "Kentuckiana Pulmonary Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "The Carl & Edyth Lindner Center for Research & Education at The Christ Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "AC-055-402: An Extension of AC-055-401, a Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument", 
        "overall_official": {
            "affiliation": "Actelion Pharmaceuticals US, Inc", 
            "last_name": "Rajiv Patni, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Frequency of treatment-emergent adverse events, serious adverse events, marked laboratory abnormalities and adverse events leading to study drug discontinuation from Baseline to Week 16.", 
            "safety_issue": "Yes", 
            "time_frame": "Visit 1 to Post-treatment safety follow-up visit (30 days after discontinuation of the study drug)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847014"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Actelion", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Actelion", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}